Royal Bank Of Canada Reaffirms “Outperform” Rating for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ)‘s stock had its “outperform” rating reiterated by investment analysts at Royal Bank Of Canada in a report issued on Monday,Benzinga reports. They presently have a $255.00 price target on the stock. Royal Bank Of Canada’s target price would suggest a potential upside of 4.30% from the company’s previous close.

JNJ has been the subject of several other reports. Daiwa Securities Group raised their target price on Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a research note on Thursday, January 29th. Barclays lifted their price target on shares of Johnson & Johnson from $217.00 to $234.00 and gave the company an “equal weight” rating in a research report on Thursday, March 19th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. Argus lifted their price target on Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. Finally, JPMorgan Chase & Co. lifted their target price on Johnson & Johnson from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $236.91.

Johnson & Johnson Stock Performance

JNJ stock opened at $244.48 on Monday. The firm has a market cap of $588.86 billion, a PE ratio of 22.12, a price-to-earnings-growth ratio of 2.40 and a beta of 0.34. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The stock has a 50-day moving average price of $238.40 and a 200-day moving average price of $211.86. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The business had revenue of $24.28 billion for the quarter. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insider Activity

In other news, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by corporate insiders.

Institutional Trading of Johnson & Johnson

Several institutional investors have recently added to or reduced their stakes in the business. AustralianSuper Pty Ltd increased its stake in shares of Johnson & Johnson by 632.0% in the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after purchasing an additional 77,000 shares in the last quarter. J.W. Cole Advisors Inc. boosted its position in Johnson & Johnson by 2.2% during the third quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock worth $24,278,000 after purchasing an additional 2,769 shares in the last quarter. Guinness Asset Management LTD grew its holdings in Johnson & Johnson by 0.4% in the third quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after purchasing an additional 5,994 shares during the period. Treasurer of the State of North Carolina increased its position in shares of Johnson & Johnson by 8.3% in the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after buying an additional 94,957 shares in the last quarter. Finally, National Pension Service increased its position in shares of Johnson & Johnson by 3.2% in the third quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after buying an additional 151,707 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royalty Pharma agreed to co‑fund J&J’s autoimmune candidate JNJ‑4804 with up to $500M, accelerating development while sharing cost/risk — a near‑term financing boost that strengthens J&J’s immunology story and could materially de‑risk future revenue upside. Royalty Pharma and J&J partner to develop autoimmune treatment
• Positive Sentiment: J&J’s recently approved oral psoriasis drug ICOTYDE showed durable 52‑week efficacy and near‑placebo safety in Phase 3/ICONIC data — a potential meaningful new product launch that bolsters immunology growth expectations. Will ICOTYDE’s First‑in‑Class Oral Psoriasis Launch Redefine J&J’s Immunology Narrative?
• Positive Sentiment: Market coverage frames the JNJ‑4804 funding pact and other immunology moves as adding heft to J&J’s growth pipeline — positive sentiment for medium‑term revenue prospects. Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story
• Positive Sentiment: An analyst shop (RBC) reaffirmed an outperform rating and set a $255 price target, signaling buy‑side support and limited near‑term upside capture by bulls. Benzinga: RBC Outperform, $255 PT
• Positive Sentiment: J&J presented encouraging randomized Phase 2 data (CONVERGE) for a radiotherapy‑adjunct asset (NBTXR3/JNJ‑1900) at a major conference — supportive for oncology pipeline valuation. NANOBIOTIX Announces Presentation of First Data
• Neutral Sentiment: Valuation and dividend analyses are being debated: some quant work questions whether JNJ remains undervalued after the rally, while other pieces emphasize its dividend‑king status and defensive appeal — these shape investor positioning but don’t change fundamentals immediately. Seeking Alpha: Is the Stock Still Undervalued?
• Neutral Sentiment: Macro risk‑off moves and a broader market rally (U.S. geopolitical headlines) have lifted many stocks; J&J’s low beta/dividend profile makes it a common safe‑haven trade in volatile sessions. Dow Jones Futures: Market Soars As Trump Signals Iran War Exit
• Negative Sentiment: Media pieces (including commentary from Jim Cramer) continue to flag past “free fall” volatility and ongoing litigation exposures, which remain an overhang on sentiment and could cap multiple expansion until legal clarity improves. Jim Cramer Highlights J&J Stock’s Free Fall and Rise

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.